<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000683767"><SummaryMetaData><SummaryType>Complementary and alternative medicine</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting.</SummaryDescription><SummaryURL xref="http://cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq">Cannabis and Cannabinoids (PDQ®)</SummaryURL><MainTopics><TermRef ref="CDR0000269131">marijuana</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000572214">nabiximols</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Cannabis and Cannabinoids (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Cannabis &amp; Cannabinoids</AltTitle><AltTitle TitleType="Short">Cannabis and Cannabinoids</AltTitle><SummarySection id="_1"><Title>Overview</Title><Para id="_2">This <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> (CAM) information summary provides an overview of the use of <ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName> and its components as a treatment for people with <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>-related <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> caused by the disease itself or  its treatment.</Para><Para id="_17">This summary contains the following key information:</Para><ItemizedList id="_18" Style="bullet" Compact="No"><ListItem><ScientificName>Cannabis</ScientificName> has been used for medicinal purposes for thousands of years.</ListItem><ListItem>By federal law, the possession of <ScientificName>Cannabis</ScientificName>, also known as marijuana, is illegal in the United States; however, a growing number of states and the District of Columbia have enacted laws to legalize its medical use.</ListItem><ListItem>The U.S. Food and Drug Administration has not approved <ScientificName>Cannabis</ScientificName> as a treatment for cancer or any other medical condition.</ListItem><ListItem><GlossaryTermRef href="CDR0000643008">Chemical</GlossaryTermRef> components of <ScientificName>Cannabis</ScientificName>, called <GlossaryTermRef href="CDR0000716077">cannabinoids</GlossaryTermRef>, <GlossaryTermRef href="CDR0000043976">activate</GlossaryTermRef> specific <GlossaryTermRef href="CDR0000044958">receptors</GlossaryTermRef> found throughout the body to produce pharmacologic effects, particularly in the <GlossaryTermRef href="CDR0000046481">central nervous system</GlossaryTermRef>  and the <GlossaryTermRef href="CDR0000046356">immune system</GlossaryTermRef>.</ListItem><ListItem>Commercially available cannabinoids, such as dronabinol and nabilone,  are approved drugs for the treatment of cancer-related side effects.</ListItem><ListItem>Cannabinoids may have benefits in the treatment of cancer-related <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_79">Many of the medical and <GlossaryTermRef href="CDR0000044724">scientific</GlossaryTermRef> terms used in this summary are hypertext linked (at first use in each section) to the <ExternalRef xref="http://www.cancer.gov/dictionary/">NCI Dictionary of Cancer Terms</ExternalRef>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. </Para><Para id="_80">Reference citations in some <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> CAM information summaries may include links to external Web sites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the Web sites, or of any treatment or product, by the PDQ Cancer CAM Editorial Board or the <GlossaryTermRef href="CDR0000044266">National Cancer Institute</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_3"><Title>General Information</Title><Para id="_4"><ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName>, also known as <GlossaryTermRef href="CDR0000285927">marijuana</GlossaryTermRef>, originated in Central Asia but is grown worldwide today.  In the United States, it is a controlled substance and is classified as a Schedule I agent (a <GlossaryTermRef href="CDR0000348921">drug</GlossaryTermRef> with increased potential for abuse and no known medical use).    The <ScientificName>Cannabis</ScientificName> plant produces a <GlossaryTermRef href="CDR0000642508">resin</GlossaryTermRef> containing psychoactive <GlossaryTermRef href="CDR0000422394">compounds</GlossaryTermRef> called <GlossaryTermRef href="CDR0000716077">cannabinoids</GlossaryTermRef>.  The highest <GlossaryTermRef href="CDR0000683342">concentration</GlossaryTermRef> of cannabinoids is found in the female flowers of the plant.<Reference refidx="1"/>  <GlossaryTermRef href="CDR0000045961">Clinical trials</GlossaryTermRef> conducted on medicinal <ScientificName>Cannabis</ScientificName> are limited. The <GlossaryTermRef href="CDR0000454785">U.S. Food and Drug Administration</GlossaryTermRef>  (FDA) has not approved the use of <ScientificName>Cannabis</ScientificName> as a treatment for any medical <GlossaryTermRef href="CDR0000651193">condition</GlossaryTermRef>. To conduct <GlossaryTermRef href="CDR0000044168">clinical</GlossaryTermRef> drug research in the United States, researchers must file an <GlossaryTermRef href="CDR0000762975">Investigational New Drug</GlossaryTermRef> (IND) application with the FDA.</Para><Para id="_19">The potential benefits of medicinal <ScientificName>Cannabis</ScientificName> for people living with <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> include <GlossaryTermRef href="CDR0000046084">antiemetic</GlossaryTermRef> effects, <GlossaryTermRef href="CDR0000454699">appetite</GlossaryTermRef> stimulation, pain relief, and improved sleep. Although few relevant surveys of practice patterns exist, it appears that <GlossaryTermRef href="CDR0000390246">physicians</GlossaryTermRef> caring for cancer patients in the United States who recommend medicinal <ScientificName>Cannabis</ScientificName> predominantly do so for <GlossaryTermRef href="CDR0000269453">symptom management</GlossaryTermRef>.<Reference refidx="2"/> A growing number of pediatric patients are seeking symptom relief with <ScientificName>Cannabis</ScientificName> or cannabinoid treatment, although studies are limited.</Para><Para id="_20">Cannabinoids are a group of terpenophenolic compounds found in <ScientificName>Cannabis</ScientificName> species (e.g., <ScientificName>Cannabis sativa </ScientificName> L.).  This summary will review the role of <ScientificName>Cannabis</ScientificName> and the cannabinoids in the treatment of people with cancer and  disease-related or treatment-related <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef>.</Para><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2" PMID="2045870">Doblin RE, Kleiman MA: Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. J Clin Oncol 9 (7): 1314-9, 1991.</Citation></ReferenceSection></SummarySection><SummarySection id="_5"><Title>History</Title><Para id="_6"><ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName> use for medicinal purposes dates back at least 3,000 years.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> It was introduced into <GlossaryTermRef href="CDR0000454743">Western medicine</GlossaryTermRef> in the 1840s by W.B. O’Shaughnessy, a <GlossaryTermRef href="CDR0000044306">surgeon</GlossaryTermRef> who learned of its medicinal properties while working in India for the British East Indies Company.  Its use was promoted for reported <GlossaryTermRef href="CDR0000045590">analgesic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000450118">sedative</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044187">anti-inflammatory</GlossaryTermRef>, antispasmodic, and <GlossaryTermRef href="CDR0000046083">anticonvulsant</GlossaryTermRef> effects.</Para><Para id="_21">In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act.  This Act imposed a levy of $1 per <GlossaryTermRef href="CDR0000330174">ounce</GlossaryTermRef> for medicinal use of <ScientificName>Cannabis</ScientificName> and $100 per ounce for recreational use.    <GlossaryTermRef href="CDR0000390246">Physicians</GlossaryTermRef> in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for <GlossaryTermRef href="CDR0000044711">prescribing</GlossaryTermRef> <ScientificName>Cannabis</ScientificName>,  use special order forms to procure it, and  keep special records concerning its professional use. In addition, the AMA believed that objective evidence that <ScientificName>Cannabis</ScientificName> was harmful was lacking and that passage of the Act would impede further research into its medicinal worth.<Reference refidx="6"/>  In 1942, <ScientificName>Cannabis</ScientificName> was removed from the U.S. <GlossaryTermRef href="CDR0000285980">Pharmacopoeia</GlossaryTermRef> because of persistent concerns about its potential to cause harm.<Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_22">In 1951, Congress passed the Boggs Act, which for the first time, included <ScientificName>Cannabis</ScientificName> with <GlossaryTermRef href="CDR0000044691">narcotic</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef>. In 1970, with the passage of the Controlled Substances Act, <GlossaryTermRef href="CDR0000285927">marijuana</GlossaryTermRef> was classified as a Schedule I drug.  Drugs in this category are distinguished as having no accepted medicinal use.  Other Schedule I substances include <GlossaryTermRef href="CDR0000641798">heroin</GlossaryTermRef>, LSD, mescaline, and methaqualone.</Para><Para id="_23">Despite  its designation as having no medicinal use, <ScientificName>Cannabis</ScientificName>  was distributed to patients by the U.S. government on a case-by-case basis under the <GlossaryTermRef href="CDR0000046526">Compassionate Use</GlossaryTermRef> <GlossaryTermRef href="CDR0000762975">Investigational New Drug</GlossaryTermRef>  program established in 1978.  Distribution of <ScientificName>Cannabis</ScientificName> through this program was discontinued in 1992.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> Although federal law prohibits the use of <ScientificName>Cannabis</ScientificName>, the table below lists the localities that permit its use for certain medical conditions.</Para><Table id="_176"><Title>List of Localities That Permit Use of <ScientificName>Cannabis</ScientificName> for Certain Medical Conditions</Title><TGroup Cols="1"><ColSpec ColName="col1" ColNum="1" ColWidth="100.00%"/><TBody><Row><entry>Alaska (AK)</entry></Row><Row><entry>Arizona (AZ)</entry></Row><Row><entry>California (CA)</entry></Row><Row><entry>Colorado (CO)</entry></Row><Row><entry>Connecticut (CT)</entry></Row><Row><entry>Delaware (DE)</entry></Row><Row><entry>District of Columbia (DC)</entry></Row><Row><entry>Hawaii (HI)</entry></Row><Row><entry>Illinois (IL)</entry></Row><Row><entry>Maine (ME)</entry></Row><Row><entry>Maryland (MD)</entry></Row><Row><entry>Massachusetts (MA)</entry></Row><Row><entry>Michigan (MI)</entry></Row><Row><entry>Minnesota (MN)</entry></Row><Row><entry>Montana (MT)</entry></Row><Row><entry>Nevada (NV)</entry></Row><Row><entry>New Hampshire (NH)</entry></Row><Row><entry>New Jersey (NJ)</entry></Row><Row><entry>New Mexico (NM)</entry></Row><Row><entry>New York (NY)</entry></Row><Row><entry>Oregon (OR)</entry></Row><Row><entry>Rhode Island (RI)</entry></Row><Row><entry>Vermont (VT)</entry></Row><Row><entry>Washington (WA)</entry></Row></TBody></TGroup></Table><Para id="_24">The main psychoactive constituent of <ScientificName>Cannabis</ScientificName> was identified as delta-9-tetrahydrocannabinol (THC).  In 1986, <GlossaryTermRef href="CDR0000462950">synthetic</GlossaryTermRef> delta-9-THC in sesame oil was licensed and approved for the treatment of <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef>-associated <GlossaryTermRef href="CDR0000390302">nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324">vomiting</GlossaryTermRef> under the <GlossaryTermRef href="CDR0000044672">generic</GlossaryTermRef> name <GlossaryTermRef href="CDR0000045240">dronabinol</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000045961">Clinical trials</GlossaryTermRef> determined that dronabinol was as effective as or better than other <GlossaryTermRef href="CDR0000046084">antiemetic</GlossaryTermRef> agents available at the time.<Reference refidx="7"/>  Dronabinol was also studied for its ability to stimulate weight gain in patients with  <GlossaryTermRef href="CDR0000045950">AIDS</GlossaryTermRef> in the late 1980s.  Thus, the indications were expanded to include treatment of anorexia associated with human immunodeficiency virus infection  in 1992. Clinical trial results showed no statistically <GlossaryTermRef href="CDR0000390271">significant</GlossaryTermRef> weight gain, although patients reported an improvement in <GlossaryTermRef href="CDR0000454699">appetite</GlossaryTermRef>.<Reference refidx="8"/><Reference refidx="9"/></Para><Para id="_25">Within the past 20 years, the neurobiology of  <GlossaryTermRef href="CDR0000716077">cannabinoids</GlossaryTermRef> has been analyzed.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/> The first cannabinoid <GlossaryTermRef href="CDR0000044958">receptor</GlossaryTermRef>, CB1, was identified in the brain in 1988.  A second cannabinoid receptor, CB2, was identified  in 1993. The highest expression of CB2 receptors is located on <GlossaryTermRef href="CDR0000044953">B lymphocytes</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044062">natural killer cells</GlossaryTermRef>, suggesting a possible role in <GlossaryTermRef href="CDR0000468803">immunity</GlossaryTermRef>.  <GlossaryTermRef href="CDR0000044026">Endogenous</GlossaryTermRef> cannabinoids (endocannabinoids) have been identified and appear to have a role in, for example, pain modulation, control of movement, feeding behavior, and memory.<Reference refidx="11"/></Para><Para id="_202">Spasticity is a common <GlossaryTermRef href="CDR0000045022">symptom</GlossaryTermRef> of <GlossaryTermRef href="CDR0000044135">multiple sclerosis</GlossaryTermRef> for which existing therapy is unsatisfactory and may include muscle stiffness, reduced mobility, and pain. In Canada, New Zealand, and some countries in Europe, nabiximols (a THC:cannabidiol extract) is approved for the treatment of spasticity associated with multiple sclerosis via oromucosal <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef>.<Reference refidx="14"/><Reference refidx="15"/> Nabiximols is also approved in Canada (under the Notice of Compliance with Conditions) for <GlossaryTermRef href="CDR0000044090">symptomatic</GlossaryTermRef> relief of pain in multiple sclerosis and <GlossaryTermRef href="CDR0000478743">advanced cancer</GlossaryTermRef>.<Reference refidx="15"/></Para><ReferenceSection><Citation idx="1">Abel EL: Marihuana, The First Twelve Thousand Years. New York: Plenum Press, 1980. <ExternalRef xref="http://www.druglibrary.org/Schaffer/hemp/history/first12000/abel.htm">Also available online</ExternalRef>. Last accessed November 5, 2014.</Citation><Citation idx="2">Joy JE, Watson SJ, Benson JA, eds.: Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999. <ExternalRef xref="http://books.nap.edu/openbook.php?isbn=0309071550">Also available online</ExternalRef>. Last accessed November 5, 2014.</Citation><Citation idx="3">Mack A, Joy J: Marijuana As Medicine? The Science Beyond the Controversy. Washington, DC: National Academy Press, 2001. <ExternalRef xref="http://books.nap.edu/openbook.php?isbn=0309065313#">Also available online</ExternalRef>. Last accessed November 5, 2014.</Citation><Citation idx="4">Booth M: Cannabis: A History. New York, NY: St Martin's Press, 2003.</Citation><Citation idx="5" PMID="19036842">Russo EB, Jiang HE, Li X, et al.: Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 59 (15): 4171-82, 2008.</Citation><Citation idx="6">Schaffer Library of Drug Policy: The Marihuana Tax Act of 1937: Taxation of Marihuana. Washington, DC: House of Representatives, Committee on Ways and Means, 1937. <ExternalRef xref="http://www.druglibrary.org/schaffer/hemp/taxact/woodward.htm">Available online</ExternalRef>.   Last accessed November 5, 2014.</Citation><Citation idx="7" PMID="1099449" MedlineID="76010695">Sallan SE, Zinberg NE, Frei E 3rd: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293 (16): 795-7, 1975.</Citation><Citation idx="8" PMID="1311935">Gorter R, Seefried M, Volberding P: Dronabinol effects on weight in patients with HIV infection. AIDS 6 (1): 127, 1992.</Citation><Citation idx="9" PMID="7730690">Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (2): 89-97, 1995.</Citation><Citation idx="10" PMID="2848184">Devane WA, Dysarz FA 3rd, Johnson MR, et al.: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (5): 605-13, 1988.</Citation><Citation idx="11" PMID="1470919">Devane WA, Hanus L, Breuer A, et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (5090): 1946-9, 1992.</Citation><Citation idx="12" PMID="21079038">Pertwee RG, Howlett AC, Abood ME, et al.: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev 62 (4): 588-631, 2010.</Citation><Citation idx="13" PMID="9597153">Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38: 179-200, 1998.</Citation><Citation idx="14" PMID="21323391">Zajicek JP, Apostu VI: Role of cannabinoids in multiple sclerosis. CNS Drugs 25 (3): 187-201, 2011.</Citation><Citation idx="15" PMID="23707385">Howard P, Twycross R, Shuster J, et al.: Cannabinoids. J Pain Symptom Manage 46 (1): 142-9, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><Title>Laboratory/Animal/Preclinical Studies</Title><Para id="_8"><GlossaryTermRef href="CDR0000716077">Cannabinoids</GlossaryTermRef> are a group of 21-carbon–containing terpenophenolic <GlossaryTermRef href="CDR0000422394">compounds</GlossaryTermRef> produced uniquely by <ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName> species (e.g., <ScientificName>Cannabis sativa</ScientificName> L.) .<Reference refidx="1"/><Reference refidx="2"/>  These plant-derived compounds may be referred to as phytocannabinoids.  Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have <GlossaryTermRef href="CDR0000390271">significant</GlossaryTermRef> <GlossaryTermRef href="CDR0000045590">analgesic</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044187">anti-inflammatory</GlossaryTermRef> activity without the psychoactive effect (high) of delta-9-THC.</Para><SummarySection id="_26"><Title>Antitumor Effects</Title><Para id="_27">One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of <GlossaryTermRef href="CDR0000046634">tumors</GlossaryTermRef>.<Reference refidx="3"/> During this 2-year study, groups of mice and rats were given various <GlossaryTermRef href="CDR0000044664">doses</GlossaryTermRef> of THC by <GlossaryTermRef href="CDR0000729771">gavage</GlossaryTermRef>.  A dose-related decrease in the <GlossaryTermRef href="CDR0000046145">incidence</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045709">hepatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000046217">adenoma</GlossaryTermRef> tumors and <GlossaryTermRef href="CDR0000046363">hepatocellular carcinoma</GlossaryTermRef> (HCC) was observed in the mice.  Decreased incidences of <GlossaryTermRef href="CDR0000046079">benign tumors</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045844">polyps</GlossaryTermRef> and adenomas) in other <GlossaryTermRef href="CDR0000257523">organs</GlossaryTermRef> (<GlossaryTermRef href="CDR0000415575">mammary gland</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046645">uterus</GlossaryTermRef>, pituitary, <GlossaryTermRef href="CDR0000367406">testis</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046254">pancreas</GlossaryTermRef>) were also noted in the rats.  In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis <GlossaryTermRef href="CDR0000270740">lung</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216">adenocarcinoma</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef> <Emphasis><GlossaryTermRef href="CDR0000045733">in vitro</GlossaryTermRef></Emphasis> and <Emphasis><GlossaryTermRef href="CDR0000046352">in vivo</GlossaryTermRef></Emphasis>.<Reference refidx="4"/>  In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_28">Cannabinoids may cause  <GlossaryTermRef href="CDR0000446109">antitumor</GlossaryTermRef> effects by various mechanisms, including <GlossaryTermRef href="CDR0000045736">induction</GlossaryTermRef> of <GlossaryTermRef href="CDR0000046476">cell</GlossaryTermRef> death, inhibition of cell growth, and inhibition of <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000046529">angiogenesis</GlossaryTermRef> invasion and <GlossaryTermRef href="CDR0000046710">metastasis</GlossaryTermRef>.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> Two reviews summarize the molecular mechanisms of action of cannabinoids as antitumor agents.<Reference refidx="13"/><Reference refidx="14"/> Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.  For example, these compounds have been shown to induce <GlossaryTermRef href="CDR0000046524">apoptosis</GlossaryTermRef> in <GlossaryTermRef href="CDR0000045700">glioma</GlossaryTermRef> cells in <GlossaryTermRef href="CDR0000476357">culture</GlossaryTermRef> and induce <GlossaryTermRef href="CDR0000046039">regression</GlossaryTermRef> of glioma tumors in mice and rats, while they protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 <GlossaryTermRef href="CDR0000044958">receptor</GlossaryTermRef>.<Reference refidx="9"/></Para><Para id="_143">The effects of delta-9-THC and a <GlossaryTermRef href="CDR0000462950">synthetic</GlossaryTermRef> agonist of the CB2 receptor were investigated in HCC.<Reference refidx="15"/> Both agents reduced the viability of HCC cells <ScientificName>in vitro</ScientificName> and demonstrated antitumor effects in HCC subcutaneous xenografts in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in <GlossaryTermRef href="CDR0000045323">non-small cell lung</GlossaryTermRef> <GlossaryTermRef href="CDR0000045963">carcinoma</GlossaryTermRef> <Reference refidx="16"/> and breast cancer.<Reference refidx="17"/></Para><Para id="_152">An <Emphasis>in vitro</Emphasis> study of the effect of CBD on programmed cell death in breast cancer cell lines found  that CBD induced programmed cell death, independent  of the CB1, CB2, or vanilloid receptors.  CBD inhibited the survival of both <GlossaryTermRef href="CDR0000045270">estrogen receptor–positive</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045272">estrogen receptor–negative</GlossaryTermRef> <GlossaryTermRef href="CDR0000444971">breast cancer</GlossaryTermRef> <GlossaryTermRef href="CDR0000044016">cell lines</GlossaryTermRef>, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic <GlossaryTermRef href="CDR0000044560">mammary</GlossaryTermRef> cells.<Reference refidx="18"/> Other studies have also shown the antitumor effect of cannabinoids (i.e., CBD and THC) in preclinical models of breast cancer.<Reference refidx="19"/><Reference refidx="20"/></Para><Para id="_154">CBD has also been demonstrated to exert a <GlossaryTermRef href="CDR0000045487">chemopreventive</GlossaryTermRef> effect in a <GlossaryTermRef href="CDR0000561606">mouse model</GlossaryTermRef> of <GlossaryTermRef href="CDR0000044237">colon cancer</GlossaryTermRef>.<Reference refidx="21"/> In this <GlossaryTermRef href="CDR0000044758">experimental</GlossaryTermRef> system, <GlossaryTermRef href="CDR0000367457">azoxymethane</GlossaryTermRef> increased <GlossaryTermRef href="CDR0000045846">premalignant</GlossaryTermRef> and malignant <GlossaryTermRef href="CDR0000046324">lesions</GlossaryTermRef> in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In <Emphasis>in vitro</Emphasis> experiments involving <GlossaryTermRef href="CDR0000444983">colorectal cancer</GlossaryTermRef> cell lines, the investigators found that CBD protected <GlossaryTermRef href="CDR0000045671">DNA</GlossaryTermRef> from oxidative damage, increased endocannabinoid levels, and reduced <GlossaryTermRef href="CDR0000046479">cell proliferation</GlossaryTermRef>. In a subsequent  study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors.<Reference refidx="22"/></Para><Para id="_155">Another investigation into the antitumor effects of CBD examined the role of intercellular adhesion molecule-1 (ICAM-1).<Reference refidx="12"/>  ICAM-1 expression has been reported to be negatively correlated with cancer <GlossaryTermRef href="CDR0000046710">metastasis.</GlossaryTermRef> In <GlossaryTermRef href="CDR0000445043">lung cancer</GlossaryTermRef> cell lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness.</Para><Para id="_29">In an <Emphasis>in vivo</Emphasis> model using severe combined immunodeficient mice, <GlossaryTermRef href="CDR0000045914">subcutaneous</GlossaryTermRef> tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines.<Reference refidx="23"/> Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice.  Tumor specimens revealed that THC had <GlossaryTermRef href="CDR0000044186">antiangiogenic</GlossaryTermRef> and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.<Reference refidx="24"/><Reference refidx="25"/></Para><Para id="_30">In addition, both plant-derived and <GlossaryTermRef href="CDR0000044026">endogenous</GlossaryTermRef> cannabinoids have been studied for anti-<GlossaryTermRef href="CDR0000373080">inflammatory</GlossaryTermRef> effects.  A mouse study demonstrated that  endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic <GlossaryTermRef href="CDR0000044042">inflammation</GlossaryTermRef>.<Reference refidx="26"/> As a result, a <GlossaryTermRef href="CDR0000044209">hypothesis</GlossaryTermRef> that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of <GlossaryTermRef href="CDR0000444983">colorectal cancer</GlossaryTermRef> has been developed.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/><Reference refidx="30"/></Para><Para id="_188">CBD may also enhance uptake of cytotoxic drugs into malignant cells. Activation of the transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human glioblastoma multiforme cells and overcome resistance to the chemotherapy agent carmustine.<Reference refidx="31"/> In an <Emphasis>in vitro</Emphasis> model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs,  leading to apoptosis of glioma cells without affecting normal human astrocytes.  This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells. Also, CBD together with THC may enhance the antitumor activity of classic chemotherapeutic drugs such as <GlossaryTermRef href="CDR0000045387">temozolomide</GlossaryTermRef> in some mouse models of cancer.<Reference refidx="13"/><Reference refidx="32"/></Para></SummarySection><SummarySection id="_32"><Title>Appetite Stimulation</Title><Para id="_33">Many <GlossaryTermRef href="CDR0000454774">animal studies</GlossaryTermRef> have previously demonstrated that delta-9-THC and other cannabinoids have a stimulatory effect on <GlossaryTermRef href="CDR0000454699">appetite</GlossaryTermRef> and increase food intake.  It is believed that the endogenous cannabinoid system may serve as a regulator of feeding behavior.  The endogenous cannabinoid anandamide potently enhances appetite in mice.<Reference refidx="33"/>  Moreover, CB1 <GlossaryTermRef href="CDR0000044958">receptors</GlossaryTermRef> in the <GlossaryTermRef href="CDR0000046359">hypothalamus</GlossaryTermRef> may be involved in the motivational or reward aspects of eating.<Reference refidx="34"/></Para></SummarySection><SummarySection id="_34"><Title>Analgesia</Title><Para id="_35">Understanding  the mechanism of cannabinoid-induced <GlossaryTermRef href="CDR0000449929">analgesia</GlossaryTermRef> has been increased through the study of cannabinoid receptors, endocannabinoids, and <GlossaryTermRef href="CDR0000462950">synthetic</GlossaryTermRef> agonists and antagonists. The CB1 receptor is found in both the <GlossaryTermRef href="CDR0000046481">central nervous system</GlossaryTermRef> (CNS) and in peripheral <GlossaryTermRef href="CDR0000373935">nerve</GlossaryTermRef> terminals.  Similar to <GlossaryTermRef href="CDR0000045054">opioid</GlossaryTermRef> receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing.<Reference refidx="35"/>  CB2 receptors, located predominantly in peripheral <GlossaryTermRef href="CDR0000046683">tissue</GlossaryTermRef>, exist at very low levels in the CNS.  With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.<Reference refidx="36"/><Reference refidx="37"/></Para><Para id="_36">Cannabinoids may also contribute to pain modulation through an anti-inflammatory mechanism; a CB2 effect with cannabinoids acting  on <GlossaryTermRef href="CDR0000044845">mast cell</GlossaryTermRef> receptors to attenuate the release of inflammatory agents, such as <GlossaryTermRef href="CDR0000657848">histamine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000335511">serotonin</GlossaryTermRef>, and on keratinocytes to enhance the release of analgesic <GlossaryTermRef href="CDR0000045054">opioids</GlossaryTermRef> has been described.<Reference refidx="38"/><Reference refidx="39"/><Reference refidx="40"/> One study reported that the efficacy of synthetic CB1- and CB2-receptor agonists were comparable with the efficacy of morphine in a murine model of tumor pain.<Reference refidx="41"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2">Grotenhermen F, Russo E, eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: The Haworth Press, 2002.</Citation><Citation idx="3" PMID="12594529">National Toxicology Program: NTP toxicology and carcinogenesis studies of 1-trans-delta(9)-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 446 (): 1-317, 1996.</Citation><Citation idx="4" PMID="16501583">Bifulco M, Laezza C, Pisanti S, et al.: Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148 (2): 123-35, 2006.</Citation><Citation idx="5" PMID="11479216">Sánchez C, de Ceballos ML, Gomez del Pulgar T, et al.: Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61 (15): 5784-9, 2001.</Citation><Citation idx="6" PMID="12091357">McKallip RJ, Lombard C, Fisher M, et al.: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2): 627-34, 2002.</Citation><Citation idx="7" PMID="12511587">Casanova ML, Blázquez C, Martínez-Palacio J, et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (1): 43-50, 2003.</Citation><Citation idx="8" PMID="15313899">Blázquez C, González-Feria L, Alvarez L, et al.: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64 (16): 5617-23, 2004.</Citation><Citation idx="9" PMID="14570037">Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (10): 745-55, 2003.</Citation><Citation idx="10" PMID="12514108">Blázquez C, Casanova ML, Planas A, et al.: Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17 (3): 529-31, 2003.</Citation><Citation idx="11" PMID="15700028">Vaccani A, Massi P, Colombo A, et al.: Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144 (8): 1032-6, 2005.</Citation><Citation idx="12" PMID="22198381">Ramer R, Bublitz K, Freimuth N, et al.: Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26 (4): 1535-48, 2012.</Citation><Citation idx="13" PMID="22555283">Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12 (6): 436-44, 2012.</Citation><Citation idx="14" PMID="24039449">Cridge BJ, Rosengren RJ: Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 5: 301-13, 2013.</Citation><Citation idx="15" PMID="21475304">Vara D, Salazar M, Olea-Herrero N, et al.: Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18 (7): 1099-111, 2011.</Citation><Citation idx="16" PMID="21097714">Preet A, Qamri Z, Nasser MW, et al.: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4 (1): 65-75, 2011.</Citation><Citation idx="17" PMID="21915267">Nasser MW, Qamri Z, Deol YS, et al.: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 6 (9): e23901, 2011.</Citation><Citation idx="18" PMID="21566064">Shrivastava A, Kuzontkoski PM, Groopman JE, et al.: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10 (7): 1161-72, 2011.</Citation><Citation idx="19" PMID="20649976">Caffarel MM, Andradas C, Mira E, et al.: Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9: 196, 2010.</Citation><Citation idx="20" PMID="20859676">McAllister SD, Murase R, Christian RT, et al.: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129 (1): 37-47, 2011.</Citation><Citation idx="21" PMID="22231745">Aviello G, Romano B, Borrelli F, et al.: Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90 (8): 925-34, 2012.</Citation><Citation idx="22" PMID="24373545">Romano B, Borrelli F, Pagano E, et al.: Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 21 (5): 631-9, 2014.</Citation><Citation idx="23" PMID="17621270">Preet A, Ganju RK, Groopman JE: Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (3): 339-46, 2008.</Citation><Citation idx="24" PMID="10861074">Zhu LX, Sharma S, Stolina M, et al.: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165 (1): 373-80, 2000.</Citation><Citation idx="25" PMID="15749859">McKallip RJ, Nagarkatti M, Nagarkatti PS: Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174 (6): 3281-9, 2005.</Citation><Citation idx="26" PMID="15085199">Massa F, Marsicano G, Hermann H, et al.: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 (8): 1202-9, 2004.</Citation><Citation idx="27" PMID="16042581">Patsos HA, Hicks DJ, Greenhough A, et al.: Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33 (Pt 4): 712-4, 2005.</Citation><Citation idx="28" PMID="20925645">Liu WM, Fowler DW, Dalgleish AG: Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol 5 (4): 281-7, 2010.</Citation><Citation idx="29" PMID="21244344">Malfitano AM, Ciaglia E, Gangemi G, et al.: Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15 (3): 297-308, 2011.</Citation><Citation idx="30" PMID="18199524">Sarfaraz S, Adhami VM, Syed DN, et al.: Cannabinoids for cancer treatment: progress and promise. Cancer Res 68 (2): 339-42, 2008.</Citation><Citation idx="31" PMID="23079154">Nabissi M, Morelli MB, Santoni M, et al.: Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34 (1): 48-57, 2013.</Citation><Citation idx="32" PMID="21220494">Torres S, Lorente M, Rodríguez-Fornés F, et al.: A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10 (1): 90-103, 2011.</Citation><Citation idx="33" PMID="16570101">Mechoulam R, Berry EM, Avraham Y, et al.: Endocannabinoids, feeding and suckling--from our perspective. Int J Obes (Lond) 30 (Suppl 1): S24-8, 2006.</Citation><Citation idx="34" PMID="15792943">Fride E, Bregman T, Kirkham TC: Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230 (4): 225-34, 2005.</Citation><Citation idx="35" PMID="10462067">Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. Life Sci 65 (6-7): 665-73, 1999.</Citation><Citation idx="36" PMID="9759727">Meng ID, Manning BH, Martin WJ, et al.: An analgesia circuit activated by cannabinoids. Nature 395 (6700): 381-3, 1998.</Citation><Citation idx="37" PMID="10518599">Walker JM, Huang SM, Strangman NM, et al.: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96 (21): 12198-203, 1999.</Citation><Citation idx="38" PMID="7724569">Facci L, Dal Toso R, Romanello S, et al.: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92 (8): 3376-80, 1995.</Citation><Citation idx="39" PMID="15705714">Ibrahim MM, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 (8): 3093-8, 2005.</Citation><Citation idx="40" PMID="9539680">Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1): 111-9, 1998.</Citation><Citation idx="41" PMID="21610490">Khasabova IA, Gielissen J, Chandiramani A, et al.: CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 22 (5-6): 607-16, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_9"><Title>Human/Clinical Studies</Title><SummarySection id="_37"><Title><ScientificName>Cannabis</ScientificName> Pharmacology</Title><Para id="_38">  When <ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName> is <GlossaryTermRef href="CDR0000044100">ingested</GlossaryTermRef> by mouth, there is a low (6%–20%) and variable <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef> <GlossaryTermRef href="CDR0000044225">bioavailability</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/>  Peak <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> concentrations of delta-9-tetrahydrocannabinol (THC) occur after 1 to 6 hours and remain elevated with a terminal half-life of 20 to 30 hours.  Taken by mouth,  delta-9-THC is initially metabolized in the <GlossaryTermRef href="CDR0000046312">liver</GlossaryTermRef> to 11-OH-THC, a potent psychoactive <GlossaryTermRef href="CDR0000462687">metabolite</GlossaryTermRef>.  When <GlossaryTermRef href="CDR0000044600">inhaled</GlossaryTermRef>, <GlossaryTermRef href="CDR0000716077">cannabinoids</GlossaryTermRef> are rapidly absorbed into the bloodstream with a peak <GlossaryTermRef href="CDR0000683342">concentration</GlossaryTermRef> in 2 to 10 minutes, declining rapidly for a period of 30 minutes and with less generation of the psychoactive 11-OH metabolite.</Para><Para id="_39">Cannabinoids are known to interact with the <GlossaryTermRef href="CDR0000045709">hepatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000390266">cytochrome P450 enzyme system</GlossaryTermRef>.<Reference refidx="3"/><Reference refidx="4"/> In one study, 24 <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> patients were treated with <GlossaryTermRef href="CDR0000046682">intravenous</GlossaryTermRef> <GlossaryTermRef href="CDR0000045391">irinotecan</GlossaryTermRef> (600 <GlossaryTermRef href="CDR0000044213">mg</GlossaryTermRef>, n = 12) or <GlossaryTermRef href="CDR0000045382">docetaxel</GlossaryTermRef> (180 mg, n = 12), followed 3 weeks later by the same <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef> <GlossaryTermRef href="CDR0000635464">concomitant</GlossaryTermRef> with medicinal <ScientificName>Cannabis</ScientificName> taken in the form of an <GlossaryTermRef href="CDR0000463714">herbal</GlossaryTermRef> tea for 15 consecutive days, starting 12 days before the second treatment.<Reference refidx="4"/> The <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef> of <ScientificName>Cannabis</ScientificName> did not significantly influence exposure to and clearance of irinotecan or docetaxel, although the herbal tea route of administration may not reproduce the effects of <GlossaryTermRef href="CDR0000044600">inhalation</GlossaryTermRef> or oral <GlossaryTermRef href="CDR0000044100">ingestion</GlossaryTermRef> of fat-<GlossaryTermRef href="CDR0000467861">soluble</GlossaryTermRef> cannabinoids.</Para></SummarySection><SummarySection id="_105"><Title>Cancer Risk</Title><Para id="_106">A number of studies have yielded conflicting evidence regarding the risks of various cancers associated with <ScientificName>Cannabis</ScientificName> use.</Para><Para id="_112">A pooled analysis of three case-cohort studies of men in northwestern Africa (430 cases and 778 controls) showed a significantly increased risk of <GlossaryTermRef href="CDR0000445043">lung cancer</GlossaryTermRef> among <GlossaryTermRef href="CDR0000439432">tobacco</GlossaryTermRef> smokers who also inhaled <ScientificName>Cannabis</ScientificName>.<Reference refidx="5"/></Para><Para id="_113">A large, <GlossaryTermRef href="CDR0000286525">retrospective cohort study</GlossaryTermRef> of 64,855 men aged 15 to 49 years from the United States found that <ScientificName>Cannabis</ScientificName> use was not associated with tobacco-related cancers and a number of other common malignancies. However, the study did find that, among nonsmokers of tobacco, ever having used <ScientificName>Cannabis</ScientificName> was associated with an increased risk of <GlossaryTermRef href="CDR0000445079">prostate cancer</GlossaryTermRef>.<Reference refidx="6"/></Para><Para id="_114"> A population-based <GlossaryTermRef href="CDR0000348989">case-control study</GlossaryTermRef> of 611 lung cancer patients revealed that chronic low <ScientificName>Cannabis</ScientificName> exposure was not associated with an increased risk of lung cancer or other upper <GlossaryTermRef href="CDR0000044811">aerodigestive tract</GlossaryTermRef> cancers and found no positive associations with any cancer type (oral, <GlossaryTermRef href="CDR0000046061">pharyngeal</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046317">laryngeal</GlossaryTermRef>, lung, or <GlossaryTermRef href="CDR0000046408">esophagus</GlossaryTermRef>) when adjusting for several confounders, including cigarette smoking.<Reference refidx="7"/></Para><Para id="_116">A systematic review <GlossaryTermRef href="CDR0000430407">assessing</GlossaryTermRef> 19 studies that evaluated <GlossaryTermRef href="CDR0000045846">premalignant</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045772">malignant</GlossaryTermRef> lung <GlossaryTermRef href="CDR0000046324">lesions</GlossaryTermRef> in persons 18 years or older who inhaled marijuana   concluded that <GlossaryTermRef href="CDR0000286105">observational studies</GlossaryTermRef> failed to demonstrate <GlossaryTermRef href="CDR0000044167">statistically significant</GlossaryTermRef> associations between marijuana inhalation and lung cancer after adjusting for tobacco use.<Reference refidx="8"/></Para><Para id="_201"><GlossaryTermRef href="CDR0000257225">Epidemiologic</GlossaryTermRef> studies examining one association of <ScientificName>Cannabis</ScientificName> use with <GlossaryTermRef href="CDR0000597171">head and neck squamous cell carcinomas</GlossaryTermRef> have also been inconsistent in their findings. A pooled analysis of nine case-control studies from the U.S./Latin  American International Head and Neck Cancer Epidemiology (INHANCE) Consortium included information from 1,921 <GlossaryTermRef href="CDR0000046024">oropharyngeal</GlossaryTermRef> cases, 356 tongue cases, and 7,639 controls. Compared with those who never smoked <ScientificName>Cannabis</ScientificName>,  <ScientificName>Cannabis</ScientificName> smokers had an elevated risk of <GlossaryTermRef href="CDR0000446523">oropharyngeal cancers</GlossaryTermRef> and a reduced risk of <GlossaryTermRef href="CDR0000390285">tongue cancer</GlossaryTermRef>.  These study results both reflect  the inconsistent  effects of cannabinoids  on cancer <GlossaryTermRef href="CDR0000046145">incidence</GlossaryTermRef> noted in previous studies and suggest that more work needs to be done to understand the potential role of <GlossaryTermRef href="CDR0000045714">human papillomavirus</GlossaryTermRef> <GlossaryTermRef href="CDR0000045364">infection</GlossaryTermRef>.<Reference refidx="9"/></Para><Para id="_177">With a <GlossaryTermRef href="CDR0000044209">hypothesis</GlossaryTermRef> that chronic marijuana use produces <GlossaryTermRef href="CDR0000044922">adverse effects</GlossaryTermRef> on the human <GlossaryTermRef href="CDR0000468796">endocrine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046564">reproductive systems</GlossaryTermRef>,  the association between marijuana use and incidence of <GlossaryTermRef href="CDR0000695185">testicular germ cell tumors</GlossaryTermRef> (TGCTs) has been examined.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> Three population-based case-control studies report an association between marijuana use and elevated risk of TGCTs, especially <GlossaryTermRef href="CDR0000046255">nonseminoma</GlossaryTermRef> or mixed-<GlossaryTermRef href="CDR0000044171">histology</GlossaryTermRef> tumors.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> However, the sample sizes in these studies were inadequate to address marijuana <GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> by  addressing associations with respect to recency, frequency, and duration of use. These  early reports of marijuana use and TGCTs establish the need for larger, well-powered, <GlossaryTermRef href="CDR0000044079">prospective studies</GlossaryTermRef>,  especially studies evaluating the role of endocannabinoid signaling and cannabinoid receptors in TGCTs.</Para><Para id="_115">A comprehensive Health Canada monograph on <GlossaryTermRef href="CDR0000285927">marijuana</GlossaryTermRef> concluded that while there are many cellular and molecular studies that provide strong evidence that inhaled marijuana is carcinogenic, the epidemiologic evidence of a link between marijuana use and cancer is still <GlossaryTermRef href="CDR0000556498">inconclusive</GlossaryTermRef>.<Reference refidx="13"/></Para></SummarySection><SummarySection id="_73"><Title>Cancer Treatment</Title><Para id="_74">No <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef> of <ScientificName>Cannabis</ScientificName> as a treatment for cancer in humans were identified in a PubMed search; however, a single, small study of intratumoral injection of delta-9-THC  in patients with recurrent glioblastoma multiforme reported potential antitumoral activity.<Reference refidx="14"/><Reference refidx="15"/></Para></SummarySection><SummarySection id="_40"><Title>Antiemetic Effect</Title><SummarySection id="_81"><Title>Cannabinoids</Title><Para id="_41">Despite advances in pharmacologic and nonpharmacologic management, <GlossaryTermRef href="CDR0000390302">nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324">vomiting</GlossaryTermRef> (N/V) remain distressing <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef> for cancer patients and their families.  <GlossaryTermRef href="CDR0000045240">Dronabinol</GlossaryTermRef>, a synthetically produced delta-9-THC,  was approved in the United States in 1986 as an <GlossaryTermRef href="CDR0000046084">antiemetic</GlossaryTermRef> to be used in cancer <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef>.  Nabilone, a <GlossaryTermRef href="CDR0000462950">synthetic</GlossaryTermRef> derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States.<Reference refidx="16"/>  Both dronabinol and nabilone have been approved by the <GlossaryTermRef href="CDR0000454785">U.S. Food and Drug Administration</GlossaryTermRef> for the treatment of N/V associated with cancer chemotherapy in patients who have failed to <GlossaryTermRef href="CDR0000044085">respond</GlossaryTermRef> to conventional antiemetic <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef>.  Numerous <GlossaryTermRef href="CDR0000044168">clinical</GlossaryTermRef> trials and meta-analyses have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.<Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/> The <ExternalRef xref="https://subscriptions.nccn.org/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf">National Comprehensive Cancer Network Guidelines</ExternalRef> recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V.</Para><Para id="_42">One systematic review studied 30 <GlossaryTermRef href="CDR0000045858">randomized</GlossaryTermRef> comparisons of delta-9-THC preparations  with <GlossaryTermRef href="CDR0000046688">placebo</GlossaryTermRef> or other antiemetics from which data on <GlossaryTermRef href="CDR0000346517">efficacy</GlossaryTermRef> and harm were available.<Reference refidx="21"/> Oral nabilone, oral dronabinol, and <GlossaryTermRef href="CDR0000044048">intramuscular</GlossaryTermRef> levonantradol (a synthetic <GlossaryTermRef href="CDR0000044919">analog</GlossaryTermRef> of dronabinol) were tested.  Inhaled <ScientificName>Cannabis</ScientificName> trials were not included.  Among all 1,366 patients included in the review, cannabinoids were found to be more effective than the conventional antiemetics <GlossaryTermRef href="CDR0000045232">prochlorperazine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045225">metoclopramide</GlossaryTermRef>, chlorpromazine, <GlossaryTermRef href="CDR0000467870">thiethylperazine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000476306">haloperidol</GlossaryTermRef>, domperidone, and alizapride. Cannabinoids, however, were not more effective for patients receiving very low or very high <GlossaryTermRef href="CDR0000454776">emetogenic</GlossaryTermRef> chemotherapy.  Side effects included a feeling of being high, <GlossaryTermRef href="CDR0000468801">euphoria</GlossaryTermRef>, <GlossaryTermRef href="CDR0000450118">sedation</GlossaryTermRef> or drowsiness,  dizziness, dysphoria or <GlossaryTermRef href="CDR0000430479">depression</GlossaryTermRef>, <GlossaryTermRef href="CDR0000476341">hallucinations</GlossaryTermRef>, <GlossaryTermRef href="CDR0000468802">paranoia</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044039">hypotension</GlossaryTermRef>.<Reference refidx="21"/> Newer antiemetics (e.g., 5-HT3 receptor antagonists) have not been directly compared with <ScientificName>Cannabis</ScientificName> or cannabinoids in cancer patients.</Para><Para id="_43">Another <GlossaryTermRef href="CDR0000390238">analysis</GlossaryTermRef> of 15 <GlossaryTermRef href="CDR0000044015">controlled studies</GlossaryTermRef> compared nabilone with placebo or available antiemetic drugs.<Reference refidx="22"/> Among 600 cancer patients, nabilone was found to be superior to prochlorperazine, domperidone, and alizapride, with nabilone favored for continuous use.</Para><Para id="_107">(Refer to  the <ScientificName><SummaryRef href="CDR0000062747#_170" url="/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq">Cannabis</SummaryRef></ScientificName> section in the PDQ summary on <SummaryRef href="CDR0000062747" url="/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq">Nausea and Vomiting</SummaryRef> for more information.)</Para></SummarySection><SummarySection id="_82"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_44">Three trials have evaluated the efficacy of inhaled marijuana in chemotherapy-induced N/V.<Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/>  In two of the studies,  inhaled <ScientificName>Cannabis</ScientificName> was  made available only after dronabinol failure.  In the first trial, no antiemetic effect was achieved with marijuana in patients receiving <GlossaryTermRef href="CDR0000045253">cyclophosphamide</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045140">doxorubicin</GlossaryTermRef>,<Reference refidx="23"/> but in the second trial, a <GlossaryTermRef href="CDR0000044167">statistically significant</GlossaryTermRef> superior  antiemetic effect  of inhaled <ScientificName>Cannabis</ScientificName> versus placebo was found among patients receiving high-dose <GlossaryTermRef href="CDR0000045393">methotrexate</GlossaryTermRef>.<Reference refidx="24"/> The third trial was a randomized, <GlossaryTermRef href="CDR0000045673">double-blind</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044840">placebo-controlled</GlossaryTermRef>, cross-over trial involving 20 adults in which both inhaled marijuana and oral THC were evaluated.  One-quarter of the patients reported a favorable antiemetic response to the cannabinoid <GlossaryTermRef href="CDR0000044737">therapies</GlossaryTermRef>. This latter study was reported in abstract form in 1984.  A full report, detailing the methods and outcomes apparently has not been published,  which limits a thorough interpretation of the significance of these findings.<Reference refidx="25"/></Para></SummarySection></SummarySection><SummarySection id="_45"><Title>Appetite Stimulation</Title><Para id="_46"><GlossaryTermRef href="CDR0000044103">Anorexia</GlossaryTermRef>, early satiety, weight loss, and <GlossaryTermRef href="CDR0000044108">cachexia</GlossaryTermRef> are problems experienced by cancer patients.  Such patients are faced not only with the disfigurement associated with wasting but also with an inability to engage in the social interaction of meals.</Para><SummarySection id="_83"><Title>Cannabinoids</Title><Para id="_48">Three <GlossaryTermRef href="CDR0000044014">controlled trials</GlossaryTermRef> demonstrated that oral THC    has variable effects on <GlossaryTermRef href="CDR0000454699">appetite</GlossaryTermRef> stimulation and  weight loss in patients with advanced malignancies and <GlossaryTermRef href="CDR0000044366">human immunodeficiency virus</GlossaryTermRef> (HIV) infection.<Reference refidx="22"/> One study evaluated whether dronabinol alone or with <GlossaryTermRef href="CDR0000046617">megestrol</GlossaryTermRef> <GlossaryTermRef href="CDR0000655020">acetate</GlossaryTermRef> was greater, less, or equal in efficacy to megestrol acetate alone for managing cancer-associated anorexia.<Reference refidx="26"/>   In this randomized, double-blind study of 469 adults with <GlossaryTermRef href="CDR0000478743">advanced cancer</GlossaryTermRef> and weight loss, patients received  2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. Appetite increased by 75% in the megestrol group and weight increased by 11%, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group after 8 to 11 weeks of treatment. These two differences were statistically <GlossaryTermRef href="CDR0000390271">significant</GlossaryTermRef>.  Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol did little to promote appetite or weight gain in advanced cancer patients compared with megestrol acetate. However, a  smaller, placebo-controlled trial of dronabinol in cancer patients demonstrated improved and enhanced chemosensory perception in the cannabinoid group—food tasted better, appetite increased, and the proportion of <GlossaryTermRef href="CDR0000044651">calories</GlossaryTermRef> consumed as <GlossaryTermRef href="CDR0000046092">protein</GlossaryTermRef> was greater than in the placebo recipients.<Reference refidx="27"/></Para><Para id="_175">In a randomized clinical trial, researchers compared the safety and effectiveness of orally administered <ScientificName>Cannabis</ScientificName> extract (2.5 mg THC and 1 mg cannabidinol), THC (2.5 mg), or placebo for the treatment of cancer-related anorexia-cachexia in 243 patients with advanced cancer who received treatment twice daily for 6 weeks.  Results demonstrated that although these agents were well tolerated by these patients, no differences were observed in patient appetite or <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef> among the three groups at this dose level and duration of <GlossaryTermRef href="CDR0000454757">intervention</GlossaryTermRef>.<Reference refidx="28"/></Para><Para id="_49">Another clinical trial that involved 139 patients with HIV or <GlossaryTermRef href="CDR0000045950">AIDS</GlossaryTermRef> and weight loss found that, compared with placebo, oral dronabinol was associated with a statistically significant increase in appetite after 4 to 6 weeks of treatment.  Patients receiving dronabinol tended to have weight stabilization, whereas patients receiving placebo continued to lose weight.<Reference refidx="29"/></Para></SummarySection><SummarySection id="_84"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_78">In trials conducted in the 1980s that involved <GlossaryTermRef href="CDR0000561403">healthy control</GlossaryTermRef> subjects, <GlossaryTermRef href="CDR0000044600">inhaling</GlossaryTermRef> <ScientificName>Cannabis</ScientificName> led to an increase in <GlossaryTermRef href="CDR0000044109">caloric intake</GlossaryTermRef>, mainly in the form of between-meal snacks, with increased intakes of fatty and sweet foods.<Reference refidx="30"/><Reference refidx="31"/> No published studies have explored the effect of inhaled <ScientificName>Cannabis</ScientificName> on appetite in cancer patients.</Para></SummarySection></SummarySection><SummarySection id="_51"><Title>Analgesia</Title><SummarySection id="_85"><Title>Cannabinoids</Title><Para id="_52">Pain management improves a patient’s quality of life throughout all <GlossaryTermRef href="CDR0000045885">stages</GlossaryTermRef> of cancer.  Through the study of cannabinoid <GlossaryTermRef href="CDR0000044958">receptors</GlossaryTermRef>, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced <GlossaryTermRef href="CDR0000449929">analgesia</GlossaryTermRef> have been analyzed.  The CB1 receptor is found in the <GlossaryTermRef href="CDR0000046481">central nervous system</GlossaryTermRef> (CNS) and in peripheral <GlossaryTermRef href="CDR0000373935">nerve</GlossaryTermRef> terminals.<Reference refidx="32"/> CB2 receptors are located mainly in peripheral <GlossaryTermRef href="CDR0000046683">tissue</GlossaryTermRef> and are expressed in only low amounts in the CNS.  Whereas only CB1 agonists exert <GlossaryTermRef href="CDR0000045590">analgesic</GlossaryTermRef> activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.<Reference refidx="33"/><Reference refidx="34"/></Para><Para id="_53">Cancer pain results from <GlossaryTermRef href="CDR0000044042">inflammation</GlossaryTermRef>, invasion of bone or other pain-sensitive structures, or nerve injury.  When cancer pain is severe and persistent, it is often resistant to treatment with <GlossaryTermRef href="CDR0000045054">opioids</GlossaryTermRef>.</Para><Para id="_54">Two studies examined the effects of oral delta-9-THC on cancer pain.  The first, a double-blind placebo-<GlossaryTermRef href="CDR0000044015">controlled study</GlossaryTermRef> involving ten patients, measured both pain intensity and pain relief.<Reference refidx="35"/> It was reported that 15 mg and 20 mg doses of the cannabinoid delta-9-THC were associated with substantial analgesic effects,  with antiemetic effects and  appetite stimulation.</Para><Para id="_55">In a <GlossaryTermRef href="CDR0000044671">follow-up</GlossaryTermRef>, single-dose study involving 36 patients, it was reported that 10 mg doses of delta-9-THC produced analgesic effects during a 7-hour <GlossaryTermRef href="CDR0000045981">observation</GlossaryTermRef> period that were comparable to 60 mg doses of codeine, and  20 mg doses of delta-9-THC induced effects equivalent to 120 mg doses of codeine.<Reference refidx="36"/> Higher doses of THC were found to be more <GlossaryTermRef href="CDR0000450118">sedative</GlossaryTermRef> than codeine.</Para><Para id="_56">Another study examined the effects of a  whole-plant <GlossaryTermRef href="CDR0000407760">extract</GlossaryTermRef> with controlled cannabinoid content in an oromucosal spray.  In a multicenter, double-blind, placebo-controlled study, the THC:cannabidiol nabiximols (THC:CBD) extract  and THC extract alone were compared in the analgesic management of patients with advanced cancer  and with moderate-to-severe cancer-related pain.  Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo.  The researchers concluded that the THC:CBD extract was efficacious for pain relief in advanced cancer patients whose pain was not fully relieved by strong opioids.<Reference refidx="37"/> In a randomized, placebo-controlled, graded-dose trial, opioid-treated cancer patients with poorly controlled <GlossaryTermRef href="CDR0000044654">chronic pain</GlossaryTermRef> demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/day), compared with placebo. Adverse events were dose related, with  only the high-dose group (11–16 sprays/day) comparing unfavorably with the placebo arm. These studies provide promising evidence of an “adjuvant analgesic” effect of  THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge.<Reference refidx="38"/> An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.<Reference refidx="39"/></Para><Para id="_194">A randomized, placebo-controlled, crossover <GlossaryTermRef href="CDR0000045838">pilot study</GlossaryTermRef> of nabiximols in 16 patients with chemotherapy-induced neuropathic pain showed no significant difference between the treatment and placebo groups. A responder analysis, however,  demonstrated that five patients reported a reduction in their pain of at least 2 points, suggesting that a larger follow-up study may be warranted.<Reference refidx="40"/></Para><Para id="_57">An <GlossaryTermRef href="CDR0000286105">observational study</GlossaryTermRef> assessed the effectiveness of nabilone in advanced cancer patients who were experiencing pain and other <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> (anorexia, depression, and <GlossaryTermRef href="CDR0000430405">anxiety</GlossaryTermRef>).  The researchers reported  that patients who used nabilone experienced improved management of pain, nausea, anxiety, and <GlossaryTermRef href="CDR0000454701">distress</GlossaryTermRef> when compared with untreated patients.  Nabilone was also associated with a decreased use of opioids, <GlossaryTermRef href="CDR0000044481">nonsteroidal anti-inflammatory drugs</GlossaryTermRef>, tricyclic <GlossaryTermRef href="CDR0000044105">antidepressants</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045039">gabapentin</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045262">dexamethasone</GlossaryTermRef>, metoclopramide, and <GlossaryTermRef href="CDR0000616146">ondansetron</GlossaryTermRef>.<Reference refidx="41"/></Para></SummarySection><SummarySection id="_86"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_157"><GlossaryTermRef href="CDR0000454774">Animal studies</GlossaryTermRef> have suggested a <GlossaryTermRef href="CDR0000330184">synergistic</GlossaryTermRef> analgesic effect when cannabinoids are combined with opioids. The results from one pharmacokinetic interaction study have been reported.  In this study, 21 patients with chronic pain were administered vaporized <ScientificName>Cannabis</ScientificName> along with sustained-release <GlossaryTermRef href="CDR0000045400">morphine</GlossaryTermRef> or <GlossaryTermRef href="CDR0000454764">oxycodone</GlossaryTermRef> for 5 days.<Reference refidx="42"/> The patients who received vaporized <ScientificName>Cannabis</ScientificName> and sustained-release morphine had a statistically significant decrease in their <GlossaryTermRef href="CDR0000285973">mean</GlossaryTermRef> pain score over the 5-day period; those who received vaporized <ScientificName>Cannabis</ScientificName> and oxycodone did not. These findings should be verified by further studies before recommendations favoring such an approach are warranted in general clinical practice.</Para><Para id="_59">Neuropathic pain is a <GlossaryTermRef href="CDR0000045022">symptom</GlossaryTermRef> cancer patients may experience, especially if treated with <GlossaryTermRef href="CDR0000045841">platinum-based</GlossaryTermRef> chemotherapy or <GlossaryTermRef href="CDR0000046138">taxanes</GlossaryTermRef>. To date, no clinical trial has examined the effectiveness of cannabinoid preparations in the treatment of chemotherapy-induced neuropathic pain.  </Para><Para id="_192">Two randomized controlled trials of inhaled <ScientificName>Cannabis</ScientificName>  in patients with <GlossaryTermRef href="CDR0000044705">peripheral neuropathy</GlossaryTermRef> or neuropathic pain of various etiologies found  that pain was reduced in patients who received inhaled <ScientificName>Cannabis</ScientificName>, compared with those who received placebo.<Reference refidx="43"/><Reference refidx="44"/> Two additional trials of inhaled <ScientificName>Cannabis</ScientificName> have also demonstrated the benefit of <ScientificName>Cannabis</ScientificName> over placebo in HIV-associated neuropathic pain.<Reference refidx="45"/><Reference refidx="46"/></Para></SummarySection></SummarySection><SummarySection id="_60"><Title>Anxiety and Sleep</Title><SummarySection id="_87"><Title><ScientificName>Cannabis</ScientificName></Title><Para id="_61">Patients often experience mood elevation after exposure to <ScientificName>Cannabis</ScientificName>, depending on their prior experience. In a five-patient <GlossaryTermRef href="CDR0000044006">case series</GlossaryTermRef> of inhaled marijuana that examined the analgesic effects of THC, it was reported that patients administered THC had improved mood, improved sense of well-being, and less anxiety.<Reference refidx="47"/></Para><Para id="_62">Another common effect of <ScientificName>Cannabis</ScientificName> is sleepiness. In a trial of a sublingual  spray, a <ScientificName>Cannabis</ScientificName>-based mixture was able to improve sleep quality.<Reference refidx="48"/> A small placebo-controlled study of dronabinol in cancer patients with <GlossaryTermRef href="CDR0000044643">altered</GlossaryTermRef> chemosensory perception also noted increased quality of sleep and relaxation in  THC-treated patients.<Reference refidx="27"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_9_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_9_19">Check NCI’s list of cancer clinical trials for cancer CAM clinical trials on <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?idtype=1&amp;id=39707&amp;tt=0&amp;format=2">dronabinol</ExternalRef>, <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?idtype=1&amp;id=269131&amp;tt=0&amp;format=2">marijuana</ExternalRef>, <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?idtype=1&amp;id=572214&amp;tt=0&amp;format=2">nabiximols</ExternalRef> and <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?idtype=1&amp;id=39760&amp;tt=0&amp;format=2">nabilone</ExternalRef> that are actively enrolling patients.</Para><Para id="_TrialSearch_9_15">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2" PMID="3012605">Agurell S, Halldin M, Lindgren JE, et al.: Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1): 21-43, 1986.</Citation><Citation idx="3" PMID="7584607">Yamamoto I, Watanabe K, Narimatsu S, et al.: Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 27 (8): 741-6, 1995.</Citation><Citation idx="4" PMID="17405893">Engels FK, de Jong FA, Sparreboom A, et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12 (3): 291-300, 2007.</Citation><Citation idx="5" PMID="19057263">Berthiller J, Straif K, Boniol M, et al.: Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 3 (12): 1398-403, 2008.</Citation><Citation idx="6" PMID="9328194">Sidney S, Quesenberry CP Jr, Friedman GD, et al.: Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8 (5): 722-8, 1997.</Citation><Citation idx="7" PMID="17035389">Hashibe M, Morgenstern H, Cui Y, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 15 (10): 1829-34, 2006.</Citation><Citation idx="8" PMID="16832000">Mehra R, Moore BA, Crothers K, et al.: The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 166 (13): 1359-67, 2006.</Citation><Citation idx="9" PMID="24351902">Marks MA, Chaturvedi AK, Kelsey K, et al.: Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. Cancer Epidemiol Biomarkers Prev 23 (1): 160-71, 2014.</Citation><Citation idx="10" PMID="19204904">Daling JR, Doody DR, Sun X, et al.: Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 115 (6): 1215-23, 2009.</Citation><Citation idx="11" PMID="20925043">Trabert B, Sigurdson AJ, Sweeney AM, et al.: Marijuana use and testicular germ cell tumors. Cancer 117 (4): 848-53, 2011.</Citation><Citation idx="12" PMID="22965656">Lacson JC, Carroll JD, Tuazon E, et al.: Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 118 (21): 5374-83, 2012.</Citation><Citation idx="13">Health Canada: Marihuana (Marijuana, Cannabis): Dried Plant for Administration by Ingestion or Other Means. Ottawa, Canada: Health Canada, 2010. <ExternalRef xref="http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php">Available online</ExternalRef>. Last accessed November 5, 2014.</Citation><Citation idx="14" PMID="16804518">Guzmán M, Duarte MJ, Blázquez C, et al.: A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95 (2): 197-203, 2006.</Citation><Citation idx="15" PMID="22555283">Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12 (6): 436-44, 2012.</Citation><Citation idx="16" PMID="17136871">Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 4 (10): 531-5, 2006 Nov-Dec.</Citation><Citation idx="17" PMID="6315040">Ahmedzai S, Carlyle DL, Calder IT, et al.: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48 (5): 657-63, 1983.</Citation><Citation idx="18" PMID="3035479">Chan HS, Correia JA, MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79 (6): 946-52, 1987.</Citation><Citation idx="19" PMID="6299551">Johansson R, Kilkku P, Groenroos M: A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 9 (Suppl B): 25-33, 1982.</Citation><Citation idx="20" PMID="3002167">Niiranen A, Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8 (4): 336-40, 1985.</Citation><Citation idx="21" PMID="11440936">Tramèr MR, Carroll D, Campbell FA, et al.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 (7303): 16-21, 2001.</Citation><Citation idx="22" PMID="16540272">Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105 (1-2): 1-25, 2006.</Citation><Citation idx="23" PMID="6261926">Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47 (7): 1746-51, 1981.</Citation><Citation idx="24" PMID="293141" MedlineID="80086122">Chang AE, Shiling DJ, Stillman RC, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91 (6): 819-24, 1979.</Citation><Citation idx="25">Levitt M, Faiman C, Hawks R, et al.: Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics. [Abstract] Proceedings of the American Society of Clinical Oncology  3: A-C354, 91, 1984.</Citation><Citation idx="26" PMID="11786587" MedlineID="21646473">Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20 (2): 567-73, 2002.</Citation><Citation idx="27" PMID="21343383">Brisbois TD, de Kock IH, Watanabe SM, et al.: Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22 (9): 2086-93, 2011.</Citation><Citation idx="28" PMID="16849753">Strasser F, Luftner D, Possinger K, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 (21): 3394-400, 2006.</Citation><Citation idx="29" PMID="7730690">Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (2): 89-97, 1995.</Citation><Citation idx="30" PMID="3774823">Foltin RW, Brady JV, Fischman MW: Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25 (3): 577-82, 1986.</Citation><Citation idx="31" PMID="3228283">Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11 (1): 1-14, 1988.</Citation><Citation idx="32" PMID="10462067">Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. Life Sci 65 (6-7): 665-73, 1999.</Citation><Citation idx="33" PMID="9685157">Calignano A, La Rana G, Giuffrida A, et al.: Control of pain initiation by endogenous cannabinoids. Nature 394 (6690): 277-81, 1998.</Citation><Citation idx="34" PMID="9734389">Fields HL, Meng ID: Watching the pot boil. Nat Med 4 (9): 1008-9, 1998.</Citation><Citation idx="35" PMID="1091664">Noyes R Jr, Brunk SF, Baram DA, et al.: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15 (2-3): 139-43, 1975 Feb-Mar.</Citation><Citation idx="36" PMID="50159">Noyes R Jr, Brunk SF, Avery DA, et al.: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18 (1): 84-9, 1975.</Citation><Citation idx="37" PMID="19896326">Johnson JR, Burnell-Nugent M, Lossignol D, et al.: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39 (2): 167-79, 2010.</Citation><Citation idx="38" PMID="22483680">Portenoy RK, Ganae-Motan ED, Allende S, et al.: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13 (5): 438-49, 2012.</Citation><Citation idx="39" PMID="23141881">Johnson JR, Lossignol D, Burnell-Nugent M, et al.: An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46 (2): 207-18, 2013.</Citation><Citation idx="40" PMID="23742737">Lynch ME, Cesar-Rittenberg P, Hohmann AG: A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 47 (1): 166-73, 2014.</Citation><Citation idx="41" PMID="18402303">Maida V, Ennis M, Irani S, et al.: Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 6 (3): 119-24, 2008.</Citation><Citation idx="42" PMID="22048225">Abrams DI, Couey P, Shade SB, et al.: Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90 (6): 844-51, 2011.</Citation><Citation idx="43" PMID="23237736">Wilsey B, Marcotte T, Deutsch R, et al.: Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 14 (2): 136-48, 2013.</Citation><Citation idx="44" PMID="18403272">Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 9 (6): 506-21, 2008.</Citation><Citation idx="45" PMID="17296917">Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68 (7): 515-21, 2007.</Citation><Citation idx="46" PMID="18688212">Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34 (3): 672-80, 2009.</Citation><Citation idx="47" PMID="4426188">Noyes R Jr, Baram DA: Cannabis analgesia. Compr Psychiatry 15 (6): 531-5, 1974 Nov-Dec.</Citation><Citation idx="48" PMID="17712817">Russo EB, Guy GW, Robson PJ: Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 4 (8): 1729-43, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_11"><Title>Adverse Effects</Title><SummarySection id="_88"><Title><ScientificName>Cannabis</ScientificName> and Cannabinoids </Title><Para id="_12">Because <GlossaryTermRef href="CDR0000716077">cannabinoid</GlossaryTermRef> receptors, unlike opioid receptors, are not located in the brainstem areas controlling respiration, lethal overdoses from <ScientificName><GlossaryTermRef href="CDR0000716285">Cannabis</GlossaryTermRef></ScientificName> and cannabinoids do not occur.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> However, cannabinoid receptors are present in other <GlossaryTermRef href="CDR0000046683">tissues</GlossaryTermRef> throughout the body, not just in the <GlossaryTermRef href="CDR0000046481">central nervous system</GlossaryTermRef>,  and <GlossaryTermRef href="CDR0000044922">adverse effects</GlossaryTermRef> include <GlossaryTermRef href="CDR0000415551">tachycardia</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044039">hypotension</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044197">conjunctival</GlossaryTermRef> injection, bronchodilation, muscle relaxation, and decreased <GlossaryTermRef href="CDR0000045692">gastrointestinal</GlossaryTermRef> motility.</Para><Para id="_75">Although cannabinoids are considered by some to be addictive drugs, their addictive potential is considerably lower than that of other <GlossaryTermRef href="CDR0000044711">prescribed</GlossaryTermRef> agents or substances of abuse.<Reference refidx="2"/><Reference refidx="4"/>  The brain develops a tolerance to cannabinoids.</Para><Para id="_76">Withdrawal <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> such as irritability, <GlossaryTermRef href="CDR0000044043">insomnia</GlossaryTermRef> with sleep <GlossaryTermRef href="CDR0000462676">electroencephalogram</GlossaryTermRef> disturbance, restlessness, <GlossaryTermRef href="CDR0000256567">hot flashes</GlossaryTermRef>, and, rarely, <GlossaryTermRef href="CDR0000390302">nausea</GlossaryTermRef> and cramping have been observed. However, these symptoms appear to be mild compared with  withdrawal symptoms associated with opiates or benzodiazepines, and the symptoms usually dissipate after a few days.</Para><Para id="_77">Unlike other commonly used drugs, cannabinoids are stored in adipose tissue and excreted at a low rate (half-life 1–3 days), so even abrupt cessation of cannabinoid intake is not associated with rapid declines in <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> concentrations that would precipitate  severe or abrupt withdrawal symptoms or drug cravings.</Para><Para id="_156">Since <ScientificName>Cannabis</ScientificName> smoke contains many of the same components as <GlossaryTermRef href="CDR0000439432">tobacco</GlossaryTermRef> smoke, there are valid concerns about the adverse <GlossaryTermRef href="CDR0000045852">pulmonary</GlossaryTermRef> effects of <GlossaryTermRef href="CDR0000044600">inhaled</GlossaryTermRef> <ScientificName>Cannabis</ScientificName>. A longitudinal study in a noncancer population evaluated repeated measurements of pulmonary function over  20 years in 5,115 men and women whose smoking histories were known.<Reference refidx="5"/> 

While tobacco exposure was associated with decreased pulmonary function, the investigators concluded that occasional and low-cumulative <ScientificName>Cannabis</ScientificName> use was not associated with adverse effects on pulmonary function (forced expiratory volume in the first second of expiration [FEV1] and forced vital capacity [FVC]).</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8972919">Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996.</Citation><Citation idx="2">Grotenhermen F, Russo E, eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: The Haworth Press, 2002.</Citation><Citation idx="3" PMID="17136871">Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 4 (10): 531-5, 2006 Nov-Dec.</Citation><Citation idx="4" PMID="14570037">Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (10): 745-55, 2003.</Citation><Citation idx="5" PMID="22235088">Pletcher MJ, Vittinghoff E, Kalhan R, et al.: Association between marijuana exposure and pulmonary function over 20 years. JAMA 307 (2): 173-81, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_13"><Title>Summary of the Evidence for Cannabis and Cannabinoids</Title><Para id="_14">To assist readers in evaluating the results of human studies of <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> (CAM)  treatments for people with <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>, the strength of the evidence (i.e., the <GlossaryTermRef href="CDR0000446533">levels of evidence</GlossaryTermRef>) associated with each type of treatment is provided whenever possible. To qualify for a level of evidence <GlossaryTermRef href="CDR0000390238">analysis</GlossaryTermRef>, a study must:</Para><ItemizedList id="_70" Style="bullet"><ListItem>Be published in a <GlossaryTermRef href="CDR0000537399">peer-reviewed scientific journal</GlossaryTermRef>.</ListItem><ListItem>Report on <GlossaryTermRef href="CDR0000043985">therapeutic</GlossaryTermRef> <GlossaryTermRef href="CDR0000467853">outcome</GlossaryTermRef> or outcomes, such as <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044085">response</GlossaryTermRef>, improvement in survival, or measured improvement in <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef>.</ListItem><ListItem>Describe <GlossaryTermRef href="CDR0000044168">clinical</GlossaryTermRef> findings in sufficient detail for a meaningful evaluation to be made.</ListItem></ItemizedList><Para id="_92">Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and <GlossaryTermRef href="CDR0000044724">scientific</GlossaryTermRef> strength of the treatment outcomes (i.e., <GlossaryTermRef href="CDR0000346519">endpoints</GlossaryTermRef>) measured. The resulting two scores are then combined to produce an overall score. An overall level of evidence score cannot be assigned to cannabinoids because there has been insufficient clinical research to date. For an explanation of possible scores and additional information about levels of evidence analysis of CAM treatments for people with cancer, refer to <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine</SummaryRef>.</Para><ItemizedList id="_90" Style="simple" Compact="No"><ListTitle>Cannabinoids</ListTitle><ListItem>Several <GlossaryTermRef href="CDR0000044014">controlled clinical trials</GlossaryTermRef> have been performed, and meta-analyses of these support a beneficial effect of cannabinoids (<GlossaryTermRef href="CDR0000045240">dronabinol</GlossaryTermRef> and nabilone) on <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef>-induced <GlossaryTermRef href="CDR0000390302">nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324">vomiting</GlossaryTermRef> (N/V) compared with <GlossaryTermRef href="CDR0000046688">placebo</GlossaryTermRef>.    Both dronabinol and nabilone are approved by the <GlossaryTermRef href="CDR0000454785">U.S. Food and Drug Administration</GlossaryTermRef> for the <GlossaryTermRef href="CDR0000439419">prevention</GlossaryTermRef> or treatment of chemotherapy-induced N/V in cancer patients but not for other symptom management or off-label use.</ListItem></ItemizedList><ItemizedList id="_91" Style="bullet" Compact="No"><ListTitle>Cannabis</ListTitle><ListItem>There have been only three small clinical trials on the use of <ScientificName>Cannabis</ScientificName> in cancer patients.  All three studies assessed <GlossaryTermRef href="CDR0000046084">antiemetic</GlossaryTermRef> activity but each explored a different patient population and chemotherapy <GlossaryTermRef href="CDR0000045864">regimen</GlossaryTermRef>.  One study demonstrated no effect, the second study showed a positive effect versus placebo, and the report of the third study did not provide enough information to characterize the overall outcome as positive or neutral.  Consequently, there are insufficient data to provide an overall level of evidence <GlossaryTermRef href="CDR0000430407">assessment</GlossaryTermRef> for the use of <ScientificName>Cannabis</ScientificName> for chemotherapy-induced N/V. Apparently, there are no published data on  the use of <ScientificName>Cannabis</ScientificName> for other cancer-related or cancer treatment–related <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>.</ListItem><ListItem>An increasing number of trials are evaluating the oromucosal <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef> of whole <ScientificName>Cannabis</ScientificName> plant <GlossaryTermRef href="CDR0000407760">extract</GlossaryTermRef> with fixed concentrations of cannabinoid components.</ListItem><ListItem>At present, there is insufficient evidence to recommend  <GlossaryTermRef href="CDR0000044600">inhaling</GlossaryTermRef>  <ScientificName>Cannabis</ScientificName> as a treatment for cancer-related symptoms or cancer treatment–related <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_15"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (12/17/2014)</Title><Para id="_16">The <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_225">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000683767#_AboutThis_1" url="http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of  Cannabis and cannabinoids in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Cannabis and Cannabinoids are:</Para><ItemizedList Style="bullet"><ListItem>Donald I. Abrams, MD (UCSF Osher Center for Integrative Medicine)</ListItem><ListItem>Nagi B. Kumar, PhD, RD, FADA (Fellow of the American Dietetic Association)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Cancer Complementary and Alternative Medicine Editorial Board uses a <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Cannabis and Cannabinoids. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq">http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection><DateFirstPublished>2011-03-16</DateFirstPublished><DateLastModified>2014-12-17</DateLastModified></Summary>
